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Abstract
Background Evidence for endoscopic vacuum therapy (EVT) for colorectal defects is still based on small patient series from 
various institutions, employing different treatment algorithms and methods. As EVT was invented at our institution 20 years 
ago, the aim was to report the efficacy and safety of EVT for colorectal defects as well as to analyze factors associated with 
efficacy, therapy duration, and outpatient treatment.
Methods Cohort study with analysis of prospectively collected data of patients receiving EVT for colorectal defects at a 
tertiary referral center in Germany (n = 281).
Results The majority of patients had malignant disease (83%) and an American Society of Anesthesiologists classification of 
III/IV (81%). Most frequent indications for EVT were anastomotic leakage after sigmoid or rectal resection (67%) followed 
by rectal stump leakage (20%). EVT was successful in 256 out of 281 patients (91%). EVT following multi-visceral resection 
(P = 0.037) and recent surgical revision after primary surgery (P = 0.009) were risk factors for EVT failure. EVT-associated 
adverse events occurred in 27 patients (10%). Median treatment duration was 25 days. Previous chemo-radiation (P = 0.006) 
was associated with a significant longer duration of EVT. Outpatient treatment was conducted in 49% of patients with a 
median hospital stay reduction of 15 days and 98% treatment success. Younger patient age (P = 0.044) was associated with 
the possibility of outpatient treatment. Restoration of intestinal continuity was achieved in 60% of patients where technically 
possible with a 12-month rate of 52%.
Conclusions In patients with colorectal defects, EVT appears to be a safe and effective, minimally invasive option for in- and 
outpatient treatment.
Keywords Endoscopic vacuum therapy · Colorectal defects · Anastomotic leakage · Complication management · Outpatient 
treatment
In recent years, the principle working mechanisms of vac-
uum-assisted wound therapy have been successfully applied 
for endoscopic treatment of various upper and lower gas-
trointestinal defects [1–3]. Active drainage of an infectious 
focus via an open-pored polyurethane sponge leads to a 
decrease in bacterial contamination, secretion, and local 
edema, while also promoting perfusion and granulation [4]. 
Endoscopic vacuum therapy (EVT) has been introduced for 
the management of gastrointestinal perforations and post-
operative defects. EVT for anastomotic leakage after rectal 
resection was developed and implemented in clinical rou-
tine at our institution at the turn of the century. In 2007, 
first results on successful EVT in 28 out of 29 patients with 
anastomotic leakage after rectal resection were published by 
our institution [1]. Today, EVT is the most commonly used 
technique for endoscopic treatment of postoperative surgi-
cal leaks. Commercial systems for EVT are distributed in 
more than 40 countries worldwide [5, 6]. However, existing 
evidence on EVT for colorectal defects is still based on a 
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few, small patient series from various institutions, employing 
different methods, treatment algorithms and materials [7]. 
In a recent review comparing 17 studies with 276 patients 
overall, success rates of EVT for treatment of anastomotic 
leakage after rectal resection range between 54 and 96% [7]. 
Treatment duration in the current literature varies between 
11 and 244 days [7]. Hence, the duration of treatment is 
one of the major concerns. However, there is still no reli-
able data on EVT as an ambulatory treatment option and no 
evidence on outpatient treatment. As EVT was invented and 
implemented into clinical routine at our institution around 
20 years ago, we have a broad experience on this technique. 
As high-volume colorectal center and due to referral of many 
patients from external institutions specifically for EVT, we 
are able to present data from a large number of consecutive 
patients treated with EVT for colorectal defects. Therefore, 
this study reports on effectiveness and safety of EVT for in- 
and outpatient treatment of colorectal defects. Furthermore, 
factors predicting therapy success and length of treatment 
for various indications are analyzed.
Patients and methods
Design and study population
Patients’ clinical data were derived from a prospective data-
base that has been maintained since the development and 
establishment of EVT at our institution in 2001. A retrospec-
tive analysis including all patients who had undergone EVT 
for colorectal defects was conducted. A diagram depicting 
the study population is shown in Fig. 1. In total, 281 patients 
treated with EVT for colorectal defects between 2001 and 
2019 were included in the study. The study was approved 
by the Ethics Committee of the Faculty of Medicine, Lud-
wig-Maximilians-University (LMU), Munich, Germany 
(approval number 19-728, 28/10/2019). The manuscript 
preparation was carried out according to the STROBE 
guidelines.
Indication and technique
In general, patients suspicious for a rectal defect after colo-
rectal surgery underwent flexible endoscopy ± computed 
tomography scan (CT). Postoperative suspicion of rectal 
leakage was based on clinical and/or laboratory deterioration 
and drain secretion. Our diagnostic and therapeutic algo-
rithm is illustrated in Fig. 2. EVT was initialized in cases 
with an extraperitoneal leakage or defect as the primary 
infectious focus.
EVT was performed as described earlier [1, 4]. In brief, 
the rectum or its concomitant infectious focus were endo-
scopically explored. After endoscopic lavage, a polyurethane 
sponge was placed either directly or by using an overtube 
device into the infectious cavity (intracavitary) or intralumi-
nal. Intracavitary EVT was performed if the leak size was 
larger than the diameter of the colonoscope allowing an easy 
intubation of the cavity. After endoscopic confirmation of 
correct sponge positioning, a vacuum bottle or pump was 
connected. Sponge changes were scheduled every 3 days. 
After successful closure of the wound cavity, the sponge was 
removed. In case of no local wound improvement or signs of 
clinical deterioration, EVT was stopped and treatment was 
adapted to surgery or endoscopic lavage.
Definition of endpoints
Treatment success was assessed during each sponge 
exchange and was defined as granulating closure of the cav-
ity, more than 90% clean and granulating tissue, decreas-
ing wound secretion, reduction of fibrinous tissue, and no 
interventional or surgical procedure required in the further 
course due to local wound healing and successful sepsis 
control (monitored clinically and by laboratory parameters). 
Figure 3 shows different stages of wound healing during 
successful EVT for anastomotic leakage. Figure 3D depicts 
a status with granulating tissue. At that point we usually 
stop EVT. EVT was either performed as in- or outpatient 
treatment. Outpatient treatment was defined as EVT that 
was conducted mainly or in part in an outpatient setting. 
Fig. 1  Distribution of EVT for 
colorectal defects (N = 281). 
Distribution of patients treated 
with endoscopic vacuum 
therapy (EVT) for colorectal 
defects between 2001 and 2019 
including 52 patients who had 
undergone surgery at external 




Fig. 2  Treatment algorithm in cases with suspected anastomotic leakage or rectal defect (CT contrast-enhanced computed tomography, EVT 
endoscopic vacuum therapy)
Fig. 3  Case showing EVT for 
treatment of an anastomotic 
leak after rectal resection. (A) 
Endoscopy in a patient with 
anastomotic leakage after low 
anterior resection showing (B) 
the extraperitoneal wound cav-
ity with fibrinous and necrotic 
tissue. After initiation of endo-
scopic vacuum therapy (EVT), 
the cavity becomes clean with 
increasing granulating tissue 
(C) until EVT can be success-
fully terminated when the cavity 




Restoration of intestinal continuity (RIC) was defined as the 
time point when the patient was free of any stoma.
Statistical analysis
Results were expressed as median and range (minimum 
and maximum). For evaluation of variables associated with 
therapy success or outpatient treatment, χ2-test and Fisher’s 
exact test (cases of low frequency) or the median test were 
used where appropriate depending on the variable. For 
identification of factors associated with therapy duration, a 
regression model was applied. For analysis of the cumula-
tive odds for RIC analysis, the Kaplan–Meier method was 
applied. P value of <0.05 was considered as statistically 
significant. For statistical analysis, SPSS statistical software 
package (version 25, IBM, Chicago, Illinois) was used.
Results
Patients’ characteristics
In a total of 281 patients (95 women, 186 men) at a median 
age of 65 years, colorectal defects were treated with EVT 
after endoscopic confirmation of diagnosis (Figs. 1, 2). 
Median time from index operation to the initiation of EVT 
(TTE) was 10 days (range: 1–91 days). Fifty-two patients 
had undergone surgery at external institutions and were 
referred to our endoscopy unit specifically for EVT. The 
colorectal defect or leakage was symptomatic in all patients 
and was associated with a relevant clinical or laboratory 
deterioration. Detailed clinical characteristics of all patients 
are shown in Table 1.
The most common underlying diseases were malignan-
cies. Colorectal cancer (CRC; primary and recurrent sig-
moid or rectal cancer, 65% of patients) was the most com-
mon diagnosis, followed by pelvic manifestation of other 
malignant tumors (non-CRC) such as locally advanced 
ovarian cancer, cancer of the cervix uteri, transitional cell 
carcinoma, gastrointestinal stroma tumors, neuroendocrine 
tumors, or uterine sarcoma. In 224 patients (80%), a stoma 
(proximal fecal diversion) had already been created before 
or within (protective or permanent) the index operation so 
that EVT was initiated after fecal diversion. In 37 patients 
(13%), a stoma was secondarily created at the time of diag-
nosis of anastomotic leak, whereas in 20 patients (7%, 35% 
of patients without fecal diversion after the index operation) 
EVT was initiated without a stoma.
Treatment duration and EVT‑associated morbidity
Median duration of EVT for the entire cohort was 25 days 
(range: 1–258 days) with a median sponge-changing interval 
of three days. A median of 8 endoscopic sessions and 7 
sponge changes per patient were observed. The duration 
stratified upon the underlying diagnosis and the indication 
Table 1  Patients’ clinical characteristics
a Symptomatic with requirement of balloon dilatation
Parameter N (%)








Previous chemo-radiation 84 (30)
Previous radiotherapy 11 (4)
Previous chemotherapy 18 (6)
Referred from external hospital for EVT 52 (19)
Underlying disease
 Sigmoid or rectal cancer 183 (65)
 Other malignancies (non-CRC) 50 (18)
 Diverticular disease 17 (6)
 Inflammatory bowel disease 12 (4)
 Perforation (traumatic, iatrogenic) 8 (3)
 Other benign diseases/tumors 11 (4)
Distant metastases (M1) 38 (14)
Multi-visceral resection 44 (16)
Indication for EVT
 Sigmoid or rectal anastomotic leakage 191 (68)
 Rectal stump leakage 56 (20)
 Deep APE wound 12 (4)
 Rectal fistula ± abscess 11 (4)
 Ileo-pouch anal anastomosis 5 (2)
 Perforation (traumatic, iatrogenic) 8 (3)
Median time from index operation to the initiation of 
EVT, days (range)
10 (1–91)
Surgical revision after primary surgery 109 (39)
Surgical revision required at EVT initialization 41 (15)
Median height of anastomotic leak N = 191, cm (range) 5.0 (0–12)
Median length of rectal stump N = 56, cm (range) 6.5 (2–15)
Median duration of EVT treatment, days (range) 25 (1–258)
Median number of sponge changes (range) 8 (0–64)
Sedation required for sponge changes (N = 227) 124 (55)
Outpatient treatment 136 (49)
Morbidity by EVT 5 (2)
 Luminal  stenosisa 16 (6)
 Rectal fistula (recto-vaginal) 7 (2)
 Bleeding 4 (1)
90-day mortality 5 (2)
EVT successful 256 (91)
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for EVT and are shown in Tables 2 and 3. Patients with 
chronic inflammatory bowel disease (IBD) tended to have 
longer treatments compared to all other patients (40 days vs. 
24 days; P = 0.118), whereas this was only significant for 
patients treated for leakage of ileo-pouch anal anastomosis 
(IPAA) (102 vs. 24 days; P = 0.009). EVT for diverticular 
disease and other benign (non-perforation) indications was 
observed to be associated with significant shorter treatment 
periods (13 vs. 27 days; P < 0.001). Previous chemo-radia-
tion (P = 0.006) and the need for sedation for sponge changes 
(P = 0.006) were significantly associated with longer dura-
tion of EVT. Of note, TTE was not linked to longer treat-
ment duration (P = 0.156). In addition, no differences were 
found between patients with and without fecal diversion 
(P = 0.438).
The subgroup analysis of patients undergoing EVT for 
anastomotic leaks revealed preoperative radiotherapy or 
chemoradiotherapy (P = 0.013), performing a total meso-
rectal excision (compared to partial mesorectal excision; 
P = 0.043), and a malignant diagnosis as indication for the 
index operation (P = 0.022) as predictive factors for elon-
gated therapy duration.
As EVT-associated morbidity, symptomatic luminal ste-
nosis occurred in 16 (6%) patients and had to be treated by 
endoscopic balloon dilation. Rectal fistulas occurred in 7 
patients (2%) after a median of 22 days after EVT initiation. 
All fistulas were recto-vaginal, and in the majority of these 
patients, initial surgery had involved resection of parts of the 
vagina or the uterus. In four patients (1%), EVT-associated 
lower gastrointestinal bleeding occurred which could be con-
trolled endoscopically in three and surgically in one patient.
Treatment success and follow‑up
In 256 patients (91%), EVT was successful and local control 
of inflammatory focus was achieved. The main reason for 
EVT failure (N = 25) was insufficient granulation with per-
sistent sepsis (N = 18, 72%). The majority of these patients 
required redo surgery. Other reasons for EVT failure were 
mortality (N = 5, 20%) and patient wish (N = 2, 8%).
The success rate depending on the underlying diagno-
sis and the indication for EVT is shown in Tables 2 and 
3. EVT following multi-visceral resection (P = 0.037), 
recent surgical revision after primary surgery (P = 0.009), 
and the duration of EVT treatment (P = 0.001) were asso-
ciated with unsuccessful treatment. Being referred from 
external hospital for EVT (P = 0.097) tended to predict 
therapy failure, however, TTE was not associated with 
unsuccessful EVT (P = 0.871). Furthermore, we did not 
find differences between patients with and without fecal 
Table 2  Duration, success rate, 
and outpatient treatment of EVT 
for colorectal defects stratified 
upon the underlying diagnosis









All patients (N = 281) 25 (1–258) 256 (91) 136 (49)
Sigmoid or rectal cancer (N = 183) 27(1–223) 170 (93) 96 (52)
Other malignancies (no-CRC; N = 50) 23 (2–258) 43 (86) 23 (46)
Diverticular disease (N = 17) 17 (6–56) 14 (82) 6 (35)
Inflammatory bowel disease (IBD, N = 12) 40 (13–151) 12 (100) 4 (12)
Perforation (traumatic, iatrogenic; N = 8) 21 (9–105) 7 (88) 3 (38)
Other benign diseases/tumors (N = 11) 12 (6–46) 10 (91) 4 (36)
Table 3  Duration, success rate, and outpatient treatment of EVT for colorectal defects stratified upon the indication for EVT
a Percentages of the respective subgroup patient number







All patients (N = 281) 25 (1–258) 256 (91) 136 (49)
Sigmoid or rectal anastomotic leakage (N = 189) 26 (1–258) 176 (93) 98 (52)
Rectal stump leakage (N = 56) 20 (7–189) 47 (84) 25 (45)
Deep APE wound (N = 12) 37 (6–223) 12 (100) 3 (25)
Rectal fistula ± abscess (N = 11) 21 (2–62) 10 (91) 7 (64)
Ileo-pouch anal anastomosis leakage (N = 5) 102 (42–151) 5 (100) 1 (20)
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diversion. The success rates were 91%, 95%, and 90% in 
patients with primary, secondary, and without fecal diver-
sion (P = 0.723). Failure of EVT was recognized rather 
early after a median of 9 days, on average after the third 
sponge exchange. Time of diagnosis or start of EVT was 
not associated with success or length of treatment. The 
possibility of outpatient treatment (success rate 98% vs. 
88%; P = 0.025) was significantly associated with therapy 
success in patients with anastomotic leak.
Restoration of intestinal continuity (RIC) was gener-
ally not possible in 60 patients (21%) due to early-phase 
mortality, performance of abdominoperineal extirpa-
tion, or oncological reasons such as extensive metastatic 
disease. In 132 out of 221 patients (60%) with possi-
ble restoration, RIC was achieved in the further course 
within a median follow-up of 6 months. In these patients, 
median time to intestinal continuity was 9 months with 
a 12-month RIC rate of 52% (Fig. 4A). When comparing 
EVT for sigmoid or rectal anastomotic leakage and rectal 
stump leakage in patients in whom RIC was technically 
possible (N = 176 and N = 24, respectively), no signifi-
cant differences were observed regarding reversal rates 
(overall rate, 63% vs. 50%) and time to RIC (9 months, 
respectively, P = 0.448). When analyzing patients with 
sigmoid or rectal resections for colorectal cancer without 
multi-visceral resections (N = 124), RIC rate revealed to 
be 68% overall within a median follow-up of 7 months. 
This tended to be better compared to patients with rectal 
stump leakage (P = 0.280, Fig. 4B).
Outpatient treatment
Primary or secondary outpatient treatment was possible in 
136 patients (49%). Primary (complete) outpatient EVT was 
conducted in 5 patients with a median duration of 31 days 
(range: 13–56) and a success rate of 100%. Secondary out-
patient treatment (continued EVT after discharge) led to a 
median reduction of 15 days (range: 1–364) of the hospital 
stay which corresponded to 46% of the total EVT duration 
in these patients. Success rate of secondary outpatient treat-
ment was 98%. Outpatient treatment stratified upon under-
lying diagnosis and treatment is shown in Tables 2 and 3. 
Younger patient age (P = 0.044) and duration of treatment 
(P < 0.001) were factors that were found to be significantly 
associated with the possibility of outpatient treatment.
Discussion
Postoperative, traumatic, or iatrogenic colorectal leaks are 
associated with a significant increase in morbidity and mor-
tality [8, 9], representing a challenging situation for both 
patient and treating physician. The reported incidence of 
postoperative anastomotic leakage ranges between 6 and 
30% with an average of 11%, depending on the height of the 
anastomosis [9, 10]. Redo operations such as Hartmann’s 
procedure are high-risk interventions with relevant mortality 
and low rates of RIC [11–13]. Therefore, a safe, effective, 
and well-validated minimally invasive technique is urgently 
needed in order to attain the best possible short- and long-
term outcomes. Even though data are still scarce, EVT 
has become the most common endoscopic technique for 
Fig. 4  Restoration of intestinal continuity. A Cumulative odds for 
restoration of intestinal continuity (RIC) after EVT for colorectal 
defects. B Comparing the odds of patients undergoing EVT for anas-
tomotic leakage following anterior (AR) and low anterior resection 
(LAR) with rectal stump leakage (RSL) where technically possible
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treatment of colorectal leaks after rectal resection [5], and 
currently, commercial systems are distributed in more than 
40 countries worldwide [5, 6]. Compared to stent applica-
tion or fibrin glue, EVT appears to be a much more versatile 
endoscopic technique because it allows for the treatment of 
defects in almost all extraperitoneal locations, regardless of 
location or size of the defect. In contrast, the usage of stents 
entails limitations that include patient discomfort and stent 
migration, hence, stent insertion should be avoided in lower 
rectal defects. Furthermore, stents can only be used for small 
abscess cavities [14]. In the case of a larger abscess cav-
ity, an additional percutaneous drainage needs to be placed; 
in contrast to EVT, stents do not allow internal drainage. 
Similarly, the use of fibrin glue comes with a limitation that 
allows it to be used only on very small leaks without any 
cavity or abscess behind [15].
A recently published review has analyzed the available 
data on EVT for colorectal defects [7]. Analyzed data in 
that review were derived from 17 different studies/case 
series, comprising 276 patients in total. Besides having a 
small sample size, included case series are characterized by 
a strong clinical heterogeneity, caused by the use of different 
materials, methods, treatment algorithms, and indications 
(e.g., no differentiation between Hartmann stump and anas-
tomotic leakage after rectal resection). Despite a large range 
in treatment success (56–97%), there was a weighted mean 
success rate of 85.3% among all included studies which is 
similar to the success rate of 91% in our large patient cohort. 
Some factors influencing success or failure of EVT have 
been identified. In contrast to some other studies [7], neo-
adjuvant chemo-radiation was not linked to EVT failure but 
to the requirement for longer treatment duration. In addition, 
we identified additional risk factors for EVT failure such as 
multi-visceral resections and recent surgical revision after 
primary surgery. Of note, the time from index operation 
to initiation of EVT had no influence on therapy success. 
Our technical experience is that older or chronic leaks are 
stiffer but respond well to EVT after thorough endoscopic 
lavage and curettage with an endoscopic brush. We also suc-
ceeded in several patients without fecal diversion. In patients 
with rectal anastomosis, in whom no protective stoma had 
been created before the diagnosis of anastomotic leakage, 
20 patients were selected for EVT without secondary fecal 
diversion. Requirements for considering EVT without 
fecal diversion are the possibility of complete intracavitary 
sponge placement with complete sealing towards the lumen 
and sufficient anal sphincter function for maintaining nega-
tive pressure. This approach was successful in 90% of the 
selected patients.
Recently, we have published detailed results of EVT for 
rectal stump leakage. EVT was conducted as intracavitary 
or intraluminal treatment with a success rate of 84% [16]. 
Preoperative radiation was shown significantly associated 
with EVT failure, and patient age represented a predictive 
factor for therapy duration [16].
Despite these promising results in the literature, there is 
currently only little evidence that EVT might be superior to 
“conventional” treatment for anastomotic leakage. Accord-
ing to a recently published small comparative study [6], EVT 
might be more effective than conventional treatment with 
regard to definite healing of postoperative leaks and long-
term preservation of intestinal continuity [6]. Here, EVT was 
associated with long-term preservation/restoration of intes-
tinal continuity in 87% compared to 38% of patients who 
had received conventional treatment. These numbers are in 
agreement with the existing literature where stoma reversal 
after leakage is performed in 30–50% of patients [17, 18], 
compared to a weighted mean rate of 76% in patients across 
studies using EVT [7].
According to our analysis, EVT appears to be a safe and 
well-tolerated procedure. In line with other studies [7], 
luminal stenosis (6%) is the most frequent adverse event. 
All stenoses were successfully treated with balloon dilata-
tion. Of note, anastomotic stenoses also occur due to chronic 
inflammation in patients who did not receive EVT and may 
be caused by the anastomotic leakage itself rather than by 
EVT [19]. In contrast to other studies [7], we observed very 
few EVT-induced recto-vaginal fistulas as EVT was strictly 
used for extraperitoneal defects only. Fistulas occurred after 
a median EVT duration of 22 days and in the majority of 
these patients, initial surgery had involved the vagina or the 
uterus suggesting that EVT might have prompted or revealed 
a leak at the vagina either.
The long duration of therapy is one of the major con-
cerns regarding EVT, and a median treatment duration of 
47 days—as calculated among 17 studies [7]—is, indeed, 
hard to justify. Another review found a median treatment 
duration of 31 days among 19 studies [20]. However, the 
median number of patients in the included studies in these 
reviews was only fifteen [7, 20]. This extensive treatment 
length with this technique might partially be explained 
by a lack of experience in the various working groups. 
For physicians who have limited experience with EVT, 
it would be a challenge to determine the correct EVT 
duration and termination. A timely decision needs to be 
made to stop EVT treatment, either because of sufficient 
or insufficient wound healing. In our cohort, median treat-
ment duration of EVT was 25 days, but this is reduced to 
17 days in benign diseases such as diverticular disease. 
Unsuccessful EVT was noted in 68% and 84% of failure 
patients during the first 14 and 21 days, respectively, and 
treatment was adapted accordingly. Consistent with the 
available literature, treatment duration was affected by 
neoadjuvant chemo-radiation. In addition, our analysis 
revealed that the type of underlying disease and the indi-
cation for EVT is linked to its duration. According to Van 
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Koperen et al. [21], the timing of EVT can additionally 
influence treatment success, with a success rate of 75% (6 
of 8 patients) when EVT was commenced within 6 weeks 
after initial surgery, compared to 38% (3 of 8) when started 
more than 6 weeks after the initial surgery [21]. Besides a 
trend in our analysis, however, we could not clearly con-
firm this finding. Of note, patients referred from external 
institutions tended to have a lower success rate.
In the current study, we have further demonstrated 
that EVT can be conducted effectively as an ambulatory 
treatment for eligible patients with a foreseeably longer 
treatment duration. Through ambulantization, the length 
of hospital stay was reduced by a median of 15 days. Suc-
cess rates of EVT were 100% and 98% for primary and 
secondary outpatient treatment, respectively. Ambulatory 
vacuum-assisted wound therapy has been successfully con-
ducted and described for other indications such as diabetic 
foot ulcers [22]. Although ambulatory EVT has not been 
described in detail before, it appears to be safe and well 
tolerated by the patients. As treatment duration seems to 
be associated with certain risk factors such as chemo-
radiation, ambulatory EVT as a treatment option should 
be discussed early especially when treating such patients. 
Besides the monetary aspects, the patients’ quality of life 
is also possibly improved by allowing treatment in sur-
roundings preferable for the patient.
In this first larger cohort study, EVT was shown to be a 
safe and effective treatment option for colorectal leaks and 
perforations. EVT might become increasingly recognized 
as an ambulatory treatment option reducing the length of 
hospital stay.
Acknowledgements The authors sincerely thank Rolf Weidenhagen, 
MD, Fritz Spelsberg, MD, Klaus Uwe Grützner, MD, and Christian 
Schneider, MD, for their preliminary work (technical development, 
clinical implementation, and scientific work) in the field of endoscopic 
vacuum therapy at our department. The authors are thankful for the 
IT support of Hans-Martin Hornung, MD. The authors acknowledge 
Serene M.L. Lee (LMU, Munich) and Matt Farber (Harvard University, 
Boston, USA) for the language revision of the paper.
Authors contributions Study conception and design: FK and TSS; 
acquisition of data: FK, TSS, UW, JZ, NB, SMH, MD, and CH; anal-
ysis and interpretation of data: FK, TSS, MB, and JW; drafting of 
the article: FK and TSS. Critical revision of the article for important 
intellectual content: UW, JZ, NB, SMH, MD, CH, MB, and JW. Final 
approval of the article: all authors.
Funding Open Access funding enabled and organized by Projekt 
DEAL.
Compliance with ethical standards 
Disclosures Dres. Florian Kühn, Ulrich Wirth, Julia Zimmermann, 
Nicola Beger, Sandro M. Hasenhütl, Moritz Drefs, Maria Burian, Jens 
Werner, and Tobias S. Schiergens have declared that no conflict of 
interest exists. This study cohort includes data of 85 patients reported 
in earlier publications by Weidenhagen et al. and Kühn et al., both 
published in Surgical Endoscopy in 2007 and 2020, respectively.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Weidenhagen R, Gruetzner KU, Wiecken T et al (2007) Endo-
scopic vacuum-assisted closure of anastomotic leakage follow-
ing anterior resection of the rectum: a new method. Surg Endosc 
22:1818–1825
 2. Kuehn F, Schiffmann L, Janisch F et al (2016) Surgical endo-
scopic vacuum therapy for defects of the upper gastrointestinal 
tract. J Gastrointest Surg 20:237–243
 3. Loske G, Schorsch T, Müller C (2011) Intraluminal and intra-
cavitary vacuum therapy for esophageal leakage: a new endo-
scopic minimally invasive approach. Endoscopy 43:540–544
 4. Kuehn F, Janisch F, Schwandner F et al (2016) Endoscopic 
vacuum therapy in colorectal surgery. J Gastrointest Surg 
20:328–334
 5. Chorti A, Stavrou G, Stelmach V et al (2020) Endoscopic repair of 
anastomotic leakage after low anterior resection for rectal cancer: 
a systematic review. Asian J Endosc Surg 13(2):141–146
 6. Kühn F, Janisch F, Schwandner F et  al (2020) Comparison 
between endoscopic vacuum therapy and conventional treatment 
for leakage after rectal resection. World J Surg 44:1277–1282
 7. Shalaby M, Emile S, Elfeki H et al (2018) Systematic review 
of endoluminal vacuum-assisted therapy as salvage treatment for 
rectal anastomotic leakage. BJS Open 3:153–160
 8. Shogan B, Carliste E, Alverdy J et al (2013) Do we know why 
colorectal anastomoses leak? J Gastrointest Surg 17:1698–1707
 9. Paun BC, Cassie S, MacLean AR et al (2010) Postoperative 
complications following surgery for rectal cancer. Ann Surg 
251:807–818
 10. Snijders HS, Wouters MW, van Leersum NJ et al (2012) Meta-
analysis of the risk for anastomotic leakage, the postoperative 
mortality caused by leakage in relation to the overall postoperative 
mortality. Eur J Surg Oncol 38:1013–1019
 11. Royo-Aznar A, Moro-Valdezate D, Martín-Arévalo J et al (2018) 
Reversal of Hartmann’s procedure: a single-centre experience of 
533 consecutive cases. Colorectal Dis 20:631–638
 12. van de Wall BJ, Draaisma WA, Schouten ES et al (2010) Con-
ventional and laparoscopic reversal of the Hartmann procedure: 
a review of literature. J Gastrointest Surg 14:743–752
 13. Roig JV, Cantos M, Balciscueta Z et al (2011) Hartmann’s opera-
tion: how often is it reversed and at what cost? A multicentre 
study. Colorectal Dis 13:e396-402
 14. Hünerbein M, Krause M, Moesta KT et al (2005) Palliation of 




 15. Chopra SS, Mrak K, Hünerbein M (2009) The effect of endo-
scopic treatment on healing of anastomotic leaks after anterior 
resection of rectal cancer. Surgery 145:182–188
 16. Kühn F, Zimmermann J, Beger N et al (2020) Endoscopic vacuum 
therapy for treatment of rectal stump leakage. Surg Endosc. https 
://doi.org/10.1007/s0046 4-020-07569 -6
 17. den Dulk M, Smit M, Peeters K et al (2007) A multivariate analy-
sis of limiting factors for stoma reversal in patients with rectal 
cancer entered into the total mesorectal excision (TME) trial: a 
retrospective study. Lancet Oncol 8:297–303
 18. Güenaga KF, Lustosa SA, Saad SS et al (2007) Ileostomy or colos-
tomy for temporary decompression of colorectal anastomosis. 
Cochrane Database Syst Rev 1:CD004647
 19. Ji WB, Kwak JM, Kim J et al (2015) Risk factors causing struc-
tural sequelae after anastomotic leakage in mid to low rectal can-
cer. World J Gastroenterol 21:5910–5917
 20. Popivanov GI, Mutafchiyski VM, Cirocchi R et al (2020) Endolu-
minal negative pressure therapy in colorectal anastomotic leaks. 
Colorectal Dis 22(3):243–253
 21. van Koperen PJ, van Berge Henegouwen MI, Rosman C et al 
(2009) The Dutch multicenter experience of the endo-sponge 
treatment for anastomotic leakage after colorectal surgery. Surg 
Endosc 23:1379–1383
 22. Fife CE, Walker D, Thomson B et al (2008) The safety of nega-
tive pressure wound therapy using vacuum-assisted closure in 
diabetic foot ulcers treated in the outpatient setting. Int Wound J. 
5(Suppl2):17–22
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
